A Phase 1 Study to Evaluate the Safety and Tolerability of a Study Drug in Subjects with Early Alzheimer's Disease (AD)

Study Overview

This study will test the safety and tolerability of an experimental study drug that may delay Alzheimer’s disease (AD) onset or slow the progression of possible AD-related damage due to protein build-up in the brain.   Methods include measuring the amount of study drug and drug-related material in the cerebrospinal fluid (CSF, the fluid surrounding the brain and spinal cord) and blood, and measuring the effect of the study drug on the levels of certain proteins associated with AD in the blood and CSF.

Study Description

The purpose of this study is to determine the safety and tolerability of multiple doses of Posiphen on subjects with early Alzheimer's Disease (AD) with up to 23-25 days of daily usage, and to implement a lumbar puncture (spinal tap) cerebrospinal fluid (CSF) study. 

Additional Information

Participants will be paid for their participation.

  • IRB Number: 1608086953
  • Research Study Identifier: TX7396
  • Principal Investigator: Martin Farlow, MD

Recruitment Status


Check to see if you pre-qualify for the study.

Are you between the ages of 55 and 85? (inclusive)

If you are filling this out for a loved one, please answer based on their information.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

Contact Us

If you need help finding a study or have any questions, please contact us at inhealth@iu.edu or by phone at (888) 264-0005.